

To: (10)(2e) @ecdc.europa.eu; (10)(2e) @eisabethinen.or.at; (10)(2e) @sam.lt; (10)(2e) @vzbb.sk; (10)(2e) @ch1.lu; (10)(2e) @iss.it; (10)(2e) @fhi.no; (10)(2e) @gov.mt; (10)(2e) @landlaeknr.is; (10)(2e) @rki.de; (10)(2e) @nijz.si; (10)(2e) @hviz.hr; (10)(2e) @szu.cz; (10)(2e) @mphs.moh.gov.cy; (10)(2e) @hpsc.ie; (10)(2e) @insa.min-saude.pt; (10)(2e) @ssi.dk; (10)(2e) @spkc.gov.lv; (10)(2e) @insp.gov.ro; (10)(2e) @tcd.ie; (10)(2e) @pzh.gov.pl; (10)(2e) @thl.fi; (10)(2e) @msssi.es; (10)(2e) @folkhalsomyndigheten.se; (10)(2e) @rivm.nl; (10)(2e) @med.uoa.gr; (10)(2e) @rivm.nl; (10)(2e) @sciensano.be; (10)(2e) @nnk.gov.hu; (10)(2e) @who.int; (10)(2e) @yahoo.com; (10)(2e) @ijzcg.me

Cc: (10)(2e) @nnk.gov.hu; (10)(2e) @agihav.lv; (10)(2e) @ages.at; (10)(2e) @thl.fi; (10)(2e) @santepubliquefrance.fr; (10)(2e) @arsnorte.min-saude.pt; (10)(2e) @hse.ie; (10)(2e) @szu.cz; (10)(2e) @mh.government.bg; (10)(2e) @mphs.moh.gov.cy; (10)(2e) @nijz.si; (10)(2e) @fmed.uniba.sk; (10)(2e) @bkus.lv; (10)(2e) @inmi.it; (10)(2e) @terviseamet.ee; (10)(2e) @ssi.dk; (10)(2e) @sam.lt; (10)(2e) @folkhalsomyndigheten.se; (10)(2e) @fhi.no; (10)(2e) @iscii.es; (10)(2e) @gov.mt; (10)(2e) @rki.de; (10)(2e) @sciensano.be; (10)(2e) @pzh.gov.pl; (10)(2e) @landlaeknr.is; (10)(2e) @hviz.hr; (10)(2e) @rivm.nl; (10)(2e) @santepubliquefrance.fr; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ec.europa.eu; (10)(2e) @ecdc.europa.eu; (10)(2e) @ecdc.europa.eu; PHE

Manager: (10)(2e) @ecdc.europa.eu; (10)(2e) @ecdc.europa.eu; (10)(2e) @santepubliquefrance.fr; (10)(2e) @santepubliquefrance.fr

From: (10)(2e)
Sent: Thur 9/17/2020 12:41:21 PM
Subject: RE: Urgent request for comment on ECDC Threat Assessment Brief on COVID Reinfection
Received: Thur 9/17/2020 12:45:01 PM

Dear (10)(2e)

Thank you for sharing this document that is very helpful.


We are generally in line with it based on what is known and the questions that it raises. We suggest to develop further in the section "Options for public health response" the issue of comparing sequences of the virus detected between the 2 infection episode to confirm/exclude reinfection. This is mentioned in the document (flowchart) but would need to be explicitly mentioned in "Considerations for PCR/antibody testing and risk management for individuals re-exposed to SARS-CoV-2 following a previous infection" (for the moment it is not). In particular the need/usefulness to define criteria (number of mutations...) to define if the 2 virus isolated in the 2 episodes are different.


We completely agree with the proposed "Future considerations to support public health action" and are initiating them for France within the mission of Santé publique France.

Best regards



(10)(2e)
 (10)(2e)
 Direction générale
 +33 (0) (10)(2e)
 Santé Publique France
 12 rue du Val d'Osne 94415 Saint-Maurice Cedex France
www.santepubliquefrance.fr





Dubbel

Dubbel